RDHL - RedHill Biopharma Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5205.27M
Enterprise Value 3166.08M
Trailing P/E N/A
Forward P/E 1-7.65
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)29.90
Price/Book (mrq)6.56
Enterprise Value/Revenue 324.19
Enterprise Value/EBITDA 6-4.06

Trading Information

Stock Price History

Beta (3Y Monthly) 1.96
52-Week Change 34.73%
S&P500 52-Week Change 31.31%
52 Week High 39.57
52 Week Low 35.13
50-Day Moving Average 37.05
200-Day Moving Average 37.70

Share Statistics

Avg Vol (3 month) 373.17k
Avg Vol (10 day) 335.8k
Shares Outstanding 528.37M
Float 13.16M
% Held by Insiders 119.10%
% Held by Institutions 129.11%
Shares Short (Jul 31, 2019) 4361.62k
Short Ratio (Jul 31, 2019) 43.19
Short % of Float (Jul 31, 2019) 4N/A
Short % of Shares Outstanding (Jul 31, 2019) 41.27%
Shares Short (prior month Jun 28, 2019) 4304.87k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-602.65%

Management Effectiveness

Return on Assets (ttm)-59.07%
Return on Equity (ttm)-133.35%

Income Statement

Revenue (ttm)6.87M
Revenue Per Share (ttm)0.26
Quarterly Revenue Growth (yoy)-33.50%
Gross Profit (ttm)5.52M
EBITDA -40.87M
Net Income Avi to Common (ttm)-38.55M
Diluted EPS (ttm)-1.47
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)34.87M
Total Cash Per Share (mrq)1.23
Total Debt (mrq)4.07M
Total Debt/Equity (mrq)12.76
Current Ratio (mrq)2.84
Book Value Per Share (mrq)1.12

Cash Flow Statement

Operating Cash Flow (ttm)-34.55M
Levered Free Cash Flow (ttm)-20.35M